Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more
Ckd Bio (063160) - Net Assets
Latest net assets as of September 2025: ₩128.67 Billion KRW
Based on the latest financial reports, Ckd Bio (063160) has net assets worth ₩128.67 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩295.23 Billion) and total liabilities (₩166.55 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩128.67 Billion |
| % of Total Assets | 43.58% |
| Annual Growth Rate | 6.32% |
| 5-Year Change | -22.36% |
| 10-Year Change | 2.85% |
| Growth Volatility | 16.2 |
Ckd Bio - Net Assets Trend (2008–2024)
This chart illustrates how Ckd Bio's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Ckd Bio (2008–2024)
The table below shows the annual net assets of Ckd Bio from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩131.01 Billion | +6.49% |
| 2023-12-31 | ₩123.02 Billion | -16.76% |
| 2022-12-31 | ₩147.80 Billion | -8.48% |
| 2021-12-31 | ₩161.49 Billion | -4.30% |
| 2020-12-31 | ₩168.75 Billion | +6.49% |
| 2019-12-31 | ₩158.46 Billion | +7.31% |
| 2018-12-31 | ₩147.66 Billion | +3.95% |
| 2017-12-31 | ₩142.05 Billion | +5.09% |
| 2016-12-31 | ₩135.16 Billion | +6.11% |
| 2015-12-31 | ₩127.38 Billion | +4.54% |
| 2014-12-31 | ₩121.85 Billion | -1.64% |
| 2013-12-31 | ₩123.87 Billion | -0.22% |
| 2012-12-31 | ₩124.15 Billion | +4.32% |
| 2011-12-31 | ₩119.00 Billion | +56.30% |
| 2010-12-31 | ₩76.14 Billion | +18.83% |
| 2009-12-31 | ₩64.08 Billion | +30.36% |
| 2008-12-31 | ₩49.15 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Ckd Bio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 909.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩88.19 Billion | 67.32% |
| Other Components | ₩42.82 Billion | 32.68% |
| Total Equity | ₩131.01 Billion | 100.00% |
Ckd Bio Competitors by Market Cap
The table below lists competitors of Ckd Bio ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Confidence Petroleum India Limited
NSE:CONFIPET
|
$44.11 Million |
|
Calidus Resources Ltd
PINK:CALRF
|
$44.11 Million |
|
Amarc Resources Ltd
OTCQB:AXREF
|
$44.13 Million |
|
Millennium Grp Corp (Asia)
BK:MGC
|
$44.14 Million |
|
Sachem Capital Corp
NYSE MKT:SACH
|
$44.10 Million |
|
Ramada Investimentos e Industria S.A
LS:RAM
|
$44.08 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
$44.07 Million |
|
GiG Software PLC
ST:GIG-SDB
|
$44.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ckd Bio's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 123,024,437,950 to 131,009,150,220, a change of 7,984,712,270 (6.5%).
- Net income of 8,700,827,330 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩8.70 Billion | +6.64% |
| Other Changes | ₩-716.12 Million | -0.55% |
| Total Change | ₩- | 6.49% |
Book Value vs Market Value Analysis
This analysis compares Ckd Bio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩26373.47 | ₩19350.00 | x |
| 2018-12-31 | ₩27416.15 | ₩19350.00 | x |
| 2019-12-31 | ₩30892.63 | ₩19350.00 | x |
| 2020-12-31 | ₩30759.97 | ₩19350.00 | x |
| 2021-12-31 | ₩29437.20 | ₩19350.00 | x |
| 2022-12-31 | ₩26941.40 | ₩19350.00 | x |
| 2023-12-31 | ₩22425.33 | ₩19350.00 | x |
| 2024-12-31 | ₩23880.81 | ₩19350.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ckd Bio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.64%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.07%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 2.17x
- Recent ROE (6.64%) is above the historical average (4.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 17.78% | 10.48% | 0.88x | 1.93x | ₩3.82 Billion |
| 2009 | 25.26% | 15.19% | 0.96x | 1.74x | ₩9.78 Billion |
| 2010 | 18.88% | 11.83% | 1.03x | 1.55x | ₩6.76 Billion |
| 2011 | 9.18% | 9.88% | 0.56x | 1.67x | ₩-979.76 Million |
| 2012 | 5.72% | 6.24% | 0.61x | 1.49x | ₩-5.31 Billion |
| 2013 | 1.34% | 1.65% | 0.57x | 1.42x | ₩-10.73 Billion |
| 2014 | -0.91% | -1.04% | 0.64x | 1.35x | ₩-13.29 Billion |
| 2015 | 5.22% | 6.24% | 0.63x | 1.34x | ₩-6.08 Billion |
| 2016 | 6.98% | 8.35% | 0.62x | 1.34x | ₩-4.08 Billion |
| 2017 | 5.64% | 6.78% | 0.66x | 1.26x | ₩-6.19 Billion |
| 2018 | 5.39% | 6.39% | 0.67x | 1.25x | ₩-6.81 Billion |
| 2019 | 7.74% | 8.94% | 0.59x | 1.47x | ₩-3.58 Billion |
| 2020 | 3.68% | 4.98% | 0.44x | 1.68x | ₩-10.67 Billion |
| 2021 | -4.07% | -4.62% | 0.48x | 1.85x | ₩-22.73 Billion |
| 2022 | -11.30% | -10.70% | 0.50x | 2.11x | ₩-31.48 Billion |
| 2023 | -19.66% | -15.09% | 0.55x | 2.39x | ₩-36.49 Billion |
| 2024 | 6.64% | 5.07% | 0.60x | 2.17x | ₩-4.40 Billion |
Industry Comparison
This section compares Ckd Bio's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $185,563,423,740
- Average return on equity (ROE) among peers: 1.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ckd Bio (063160) | ₩128.67 Billion | 17.78% | 1.29x | $44.11 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $75.32 Million |
| Yuhan Corp. (000100) | $323.58 Billion | 10.19% | 0.72x | $4.21 Billion |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $26.44 Million |
| Ildong Holdings Co Ltd (000230) | $66.98 Billion | 10.88% | 1.80x | $49.55 Million |
| Samil Pharm (000520) | $62.87 Billion | 0.00% | 0.77x | $110.58 Million |
| Donga Socio Holdings (000640) | $328.69 Billion | 10.58% | 1.17x | $206.35 Million |
| Jw Pharmac (001060) | $223.83 Billion | 0.28% | 1.65x | $278.34 Million |
| JW Pharmaceutical Corp (001067) | $265.44 Billion | 13.94% | 1.43x | $489.75 Million |
| Samsung Pharm (001360) | $77.58 Billion | -31.98% | 0.20x | $65.82 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $148.25 Billion | 1.71% | 0.47x | $27.39 Million |